Ceftolozane/Tazobactam + Piperacillin/Tazobactam
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ventilator-Associated Pneumonia (VAP)
Conditions
Ventilator-Associated Pneumonia (VAP)
Trial Timeline
Jun 14, 2013 → Dec 8, 2013
NCT ID
NCT01853982About Ceftolozane/Tazobactam + Piperacillin/Tazobactam
Ceftolozane/Tazobactam + Piperacillin/Tazobactam is a phase 3 stage product being developed by Merck for Ventilator-Associated Pneumonia (VAP). The current trial status is terminated. This product is registered under clinical trial identifier NCT01853982. Target conditions include Ventilator-Associated Pneumonia (VAP).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01853982 | Phase 3 | Terminated |
Competing Products
4 competing products in Ventilator-Associated Pneumonia (VAP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Doripenem + Imipenem-Cilastatin + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem | Johnson & Johnson | Phase 2 | 52 |
| Vancomycin + Linezolid | Pfizer | Approved | 84 |
| IC43 + Placebo | Valneva SE | Phase 2 | 47 |